Abstract

 CADTH recommends that Imfinzi should be reimbursed by public drug plans for the treatment of locally advanced or metastatic biliary tract cancer (BTC) if certain conditions are met.
 Imfinzi in combination with gemcitabine plus platinum-based chemotherapy should only be covered to treat patients with locally advanced or metastatic BTC who have not received prior treatment. Patients receiving Imfinzi should be in relatively good health (i.e., have a good performance status, as determined by a specialist).
 Imfinzi should only be reimbursed when it is used in combination with gemcitabine and platinum-based chemotherapy, if prescribed by specialists with experience in managing BTC, and if the cost of Imfinzi is reduced. Imfinzi should not be reimbursed if it is used to treat patients with Ampulla of Vater (AoV) cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
